Ben Wiegand, global head of the World without Disease Accelerator at Janssen, the Pharmaceutical Companies of Johnson & Johnson, talks about efforts to prevent a disease or to identify it in its earliest stages for more effective treatments.
Advancing Efforts in Disease Interception
Welcome to Scientific American’s Science Talk, posted on February 27, 2020. I’m Steve Mirsky. On this episode:
That’s Ben Wiegand. He received a doctorate in physical chemistry from Harvard. You may have seen bumper stickers that say, “Honk if You Passed P. Chem.” Wiegand is now the Global Head of the World without Disease Accelerator, the WWDA, at Janssen, the Pharmaceutical Companies of Johnson & Johnson, where he’s involved in multiple efforts to prevent disease or identify it in its earliest stages for more effective treatments. We spoke by phone.
That’s it for this episode. Get your science news at our Website (www.scientificamerican.com.), where we’re bringing you the latest news and insights about coronavirus.
And don’t forget to follow us on Twitter, where you’ll get a tweet whenever a new item hits the Web site. Our twitter name is @sciam. For Scientific American’s Science Talk, I’m Steve Mirsky. Thanks for clicking on us.